Monopar Therapeutics announces issuance of U.S. patent for camsirubicin analogs

Monopar Therapeutics announced the issuance of a U.S. patent covering compositions of matter for a novel family of camsirubicin analogs. The patent, which expands the Company's camsirubicin intellectual property portfolio, is expected to expire in 2038 not including any patent term extensions. Doxorubicin is FDA approved in 14 different types of cancers including soft tissue and bone sarcomas; metastatic stomach, ovarian, thyroid, lung, and breast cancer; acute myeloid and lymphoblastic leukemia; Hodgkin and non-Hodgkin lymphoma; and neuroblastoma. However, cumulative dose effects of doxorubicin can result in irreversible heart damage and death, which is why a restrictive lifetime cumulative dose limitation has been placed on its use. Monopar's clinical trial collaboration partner, Grupo Espanol de Investigacion en Sarcomas, an internationally renowned non-profit organization focused on the research and development of drugs for sarcomas, is on track to initiate an open-label Phase 2 clinical study in early 2021 evaluating camsirubicin head-to-head against doxorubicin in advanced soft tissue sarcoma, where doxorubicin is currently the first-line treatment.